Translation of MRS for determining human pathology into the clinic: acceptance testing for breast, prostate and barrett' [ 2003 - 2004 ]

Research Grant

Researchers: Prof Carolyn Mountford (Principal investigator) ,  A/Pr Peter Malycha ,  Prof Peter Russell

Brief description Magnetic resonance spectroscopy (MRS), for many organs, provides the pathological diagnosis with an accuracy approaching 100%. In the case of breast lesions, it discriminates accurately between benign and malignant and, for overt carcinomas, predicts the status of the regional lymph nodes without the need to biopsy the node. For some lesions, such as Barrett’s oesophagus, distinction between dysplasia’s of no immediate concern to the patient and those apparently committed to early progression to clinical cancer, can be made by the MRS method. A statistical classification method, (SCS) has been developed whereby there are now mathematical classifiers available for the testing acceptance of the method in the clinical setting. Acceptance testing of MRS technology, with the mathematical classifiers integrated in the automated software, for the pathology and prognosis from a biopsy specimen in: ·           Breast clinic (Dr Malycha, Royal Adelaide) for both pathology and nodal involvement from fine needle aspiration biopsy ·           Gastrointestinal clinic (Dr Falk. Strathfield Private) for Barrett’s oesophagus ·           Urology clinic (Dr Katelaris, Sydney Adventist Hospital) for prostate.

Funding Amount $AUD 160,000.00

Funding Scheme NHMRC Development Grants

Notes Development Grant